Clinical trials: Hyperkalemia
Hyperkalemia
Hyperkalemia Quality Improvement Program (HK-QIP) Study
This is a prospective, multi-center, single-arm study to evaluate the impact of implementation of guideline determined medical therapy (GDMT) for quality control improvement in non-dialysis chronic kidney disease (CKD-ND)…
- Trial name
- HK-QIP (NCT06884267)
- Testing
- standard hyperkalemia management implementation
- Where
- 49 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Hyperkalemia, Renal Insufficiency, Chronic
Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects
This is a multicentre, 2-part, single-blind, randomised, withdrawal, placebo-controlled study, that includes a 4-week patiromer treatment phase (Part A) followed by an 8-week randomised placebo-controlled withdrawal phase (Part…
- Trial name
- Patiromer JADE (NCT05136664)
- Testing
- Patiromer Powder for Oral Suspension (Part A), Patiromer Powder for Orals Suspension (Part B)
- Where
- 28 sites in China
- Volunteers
- 262 people
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
Hyperkalemia
A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia
This clinical trial consists of 2 parts, Part A and Part B. Part A consists of a 2-day randomized, double-blind, placebo-controlled corrective phase (CP) and a 28-day randomized, double-blind, placebo-controlled maintenance phase…
- Trial name
- NCT07251309
- Testing
- WS016
- Where
- 50 sites in China
- Volunteers
- 420 people
- Sponsor
- Waterstone Pharmaceutical (Wuhan) Co., LTD.
Hyperkalaemia, Chronic Kidney Disease
Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study
This is an open-label, randomised study in participants with chronic kidney disease (CKD) treated for hyperkalaemia (HK) whilst in hospital.
- Trial name
- CONTINUITY (NCT05347693)
- Testing
- Sodium Zirconium Cyclosilicate (SZC), Local standard of care
- Where
- 28 sites in Belgium, France and 4 more
- Volunteers
- 186 people
- Sponsor
- AstraZeneca
Hyperkalemia, End Stage Renal Disease
Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
The purpose of this study is to determine whether once-daily dosing of patiromer will reduce the frequency of hyperkalemic episodes in ESRD (end stage renal disease) study participants who receive conventional hemodialysis (HD).
- Trial name
- NCT03781089
- Testing
- Patiromer Oral Powder Product
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Duke University
Hyperkalemia
Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions
To investigate the impact of reminders for serum potassium monitoring and of hyperkalemia alerts during potassium-increasing drug-drug-interactions.
- Trial name
- NCT02020317
- Testing
- decision support in potassium-inc. drug-drug-interactions
- Where
- Switzerland
- Volunteers
- 3,341 people
- Sponsor
- University of Zurich
Chronic Kidney Diseases
Keeping RAASi Treatment With Optimal Potassium Control
Phase III, multicenter, randomized, open-label, parallel-group, non-inferiority, phase III clinical trial comparing CSZ (Lokelma) vs. iSRAA discontinuation/reduction and/or ARM (standard treatment).
- Trial name
- KEEP-ON (NCT06578533)
- Testing
- Sodium Zirconium Cyclosilicate
- Where
- 5 sites in Spain
- Volunteers
- 78 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Kidney Disease, Nephropathy
VA NEPHRON-D: Diabetes iN Nephropathy Study
Diabetes is the leading cause of end-stage renal disease (ESRD) in the United States. The overall rate of ESRD secondary to diabetes has risen 68% since 1992.
- Conditions
- Kidney Disease, Nephropathy, Type 2 Diabetes
- Trial name
- VA NEPHRON-D (NCT00555217)
- Testing
- losartan, lisinopril
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 1,448 people
- Sponsor
- US Department of Veterans Affairs
Hyperkalemia, Diminished Renal Excretion
Evidence for Potassium Restriction in Hemodialysis
EvoKe-HD is a pilot randomized controlled trial to assess the feasibility and potential for efficacy of a novel dietary approach to hyperkalemia.
- Trial name
- EvoKe-HD (NCT06120608)
- Testing
- Novel dietary approach focused on restricting the intake of highly bioavailable potassium, Traditional approach
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Chronic Kidney Disease (CKD), Hyperkalemia
Chronic Kidney Disease, Hyperkalemia and Echocardiographic Changes
Patients with CKD ( eGFR \< \<60 mL/min/1,73 m2) presenting to emergency department with isolated hyperkalemia will be study population. Pre and post treatment ECG and echocardiographic findings will be recorded.
- Conditions
- Chronic Kidney Disease (CKD), Hyperkalemia, Hemodialysis
- Trial name
- NCT06635590
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Saglik Bilimleri Universitesi
Hyperkalemia
A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia
To evaluate the efficacy of two different doses (5 and 10 g) of ZS orally administered once daily (qd) vs placebo in maintaining normokalemia in initially hyperkalemic patients having achieved normokalemia following two days of…
- Trial name
- HARMONIZE GL (NCT02875834)
- Testing
- Sodium Zirconium Cyclosilicate (ZS) 10g, Sodium Zirconium Cyclosilicate (ZS) 5g
- Where
- 45 sites in Japan, Russia and 2 more
- Volunteers
- 267 people
- Sponsor
- AstraZeneca
Hyperkalemia
Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia
It is hypothesized that SPS is more effective than placebo control (alternative hypothesis) in lowering i-STAT potassium levels in subjects with i-STAT potassium levels between 5.0 - 6.5 mmol/l versus no difference between SPS…
- Trial name
- NCT01866709
- Testing
- Sodium polystyrene sulfonate, Silicified microcrystalline cellulose
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- ZS Pharma, Inc.
Heart Failure
Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
This is an international, multicentre, parallel-group, randomised, double-blind, placebo controlled, phase II study to evaluate the benefits and risks of using sodium zirconium cyclosilicate (ZS) to initiate and intensify renin…
- Trial name
- PRIORITIZE HF (NCT03532009)
- Testing
- Sodium Zirconium Cyclosilicate
- Where
- 76 sites in United States, Brazil and 7 more
- Volunteers
- 182 people
- Sponsor
- AstraZeneca
Heart Failure, Chronic Kidney Diseases
A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients
Heart failure (HF) and Chronic Kidney Disease (CKD) patients are frequently not administered renin-angiotensin aldosterone system inhibitor (RAASi) therapies at recommended doses due to hyperkalaemia, despite proven mortality and…
- Trial name
- SENEKA (NCT06578078)
- Testing
- Sodium Zirconium Cyclosilicate, Standard of care treatment (RAASi therapy)
- Where
- 6 sites in Spain
- Volunteers
- 94 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Type2 Diabetes, Hyperkalemia
Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On
Patiromer add-on to a mineralocorticoid receptor antagonist (MRA) in patients with Type 2 diabetes mellitus and chronic kidney disease (CKD) will reduce blood pressure and left ventricular (LV) mass to a greater extent compared…
- Trial name
- MAGMAAddOn (NCT03597035)
- Testing
- Spironolactone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University Hospitals Cleveland Medical Center
Ventricular Arrhythmias and Cardiac Arrest, Implantable Defibrillator User
Targeted Potassium Levels for Prevention of ICD Therapy
This study evaluates whether a rigorously controlled high-normal level of serum-potassium (4.5-5.0 mEq/L) using dietary recommendations, potassium supplements and mineralocorticoid receptor antagonists will results in a lower…
- Conditions
- Ventricular Arrhythmias and Cardiac Arrest, Implantable Defibrillator User, Hypokalemia, Hyperkalemia
- Trial name
- NCT03833089
- Testing
- Targeted serum potassium level
- Where
- 3 sites in Denmark
- Volunteers
- 1,200 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Heart Failure, Diabetic Kidney Disease
Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study
This study evaluates the safety of finerenone compared with alternate-day spironolactone in patients with heart failure and diabetic kidney disease at increased risk of hyperkalemia.
- Conditions
- Heart Failure, Diabetic Kidney Disease, Hyperkalemia
- Trial name
- SAFE-K (NCT07523867)
- Testing
- Finerenone, Spironolactone (drug)
- Volunteers
- 60 people
- Sponsor
- Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Hyperkalemia, Chronic Kidney Disease
Prediction of Hyperkalemia in Dialysis Patients Through Waveform Analysis Using Wearable ECG
This study aims to evaluate whether hyperkalemia, a potentially life-threatening condition in dialysis patients, can be detected early using a wearable single-lead ECG device.
- Trial name
- NCT07054905
- Testing
- HiCardi wearable ECG
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Kyungho Park
Kidney Failure, Chronic
Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
The Investigator hypothesize that a single dose of patiromer will lower serum potassium levels in less than 6hrs. Since a dosage of 30g/day for a period of 4 weeks has been studied in at least two multicenter randomized…
- Trial name
- NCT02933450
- Testing
- Patiromer 25.2 g
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Baylor College of Medicine
Chronic Kidney Disease
Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD
What is this study about? This clinical trial is designed to learn how potassium from different types of food affects blood potassium levels and overall health in people with chronic kidney disease (CKD, stages 3B-5).
- Trial name
- K-HANDLE CKD (NCT06920914)
- Testing
- Low-potassium, ultra-processed diet, Low-potassium, minimally processed diet, Normal potassium-rich, minimally processed diet
- Volunteers
- 48 people
- Sponsor
- University of Alberta